Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13741194 | 0.91 | PKM (0.49) | PKMMEN1KMT2AKDM4ECCR2 | |
| SCHEMBL8223850 | 0.90 | KDM4E (0.48) | PKMMEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL13005299 | 0.84 | ACHE (0.57) | MEN1KMT2AKDM4ESIGMAR1CYP1A2 | |
| SCHEMBL13676574 | 0.84 | ACHE (0.57) | MEN1KMT2AKDM4ESIGMAR1CYP1A2 | |
| SCHEMBL13676573 | 0.84 | ACHE (0.57) | MEN1KMT2AKDM4ESIGMAR1CYP1A2 | |
| SCHEMBL9976597 | 0.82 | CHRNB2 (0.55) | KMT2AKDM4ESIGMAR1TRPV6ALDH1A1 | |
| Dimethylamine SCHEMBL27829630 | 0.80 | BACE1 (0.53) | CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL12767101 | 0.79 | PKM (0.46) | PKMMEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL25531003 | 0.79 | SIGMAR1 (0.50) | MEN1KMT2AKDM4ESIGMAR1LMNA | |
| SCHEMBL14197749 | 0.79 | HRH3 (0.54) | PKMMEN1KMT2AKDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202887-B2 | 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors | JANSSEN R&D IRELAND (IE) | 2012-06-19 | — | — | US | disclosed |
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SPINT2, PEPD, DNPEP | PKM 2107/4885MEN1 4809/4885KMT2A 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.